Teva, mAbxience expand strategic partnership to include additional oncology biosimilar candidate
by
Contributor since / Followers
Contributor since / Followers
2 months ago
JHVEPhoto/iStock Editorial via Getty Images
- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (NYSE:TEVA), and mAbxience, Thursday reported a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate.
- This marks the second agreement between the two companies, and further strengthens the alliance between Teva (TEVA) and mAbxience.
- The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States, and aligns with mAbxience’s strategy for global expansion.
- Similar to the initial contract, under the terms of this agreement, mAbxience will lead the development and production of the biosimilar, utilizing its cGMP-compliant facilities in Spain and Argentina.
- Teva (TEVA) will manage regulatory approvals and oversee commercialization in the designated markets.
- Source: Press Release